Biohaven Pharma (BHVN) Prices 5.26M Share Offering at $47.50/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/25/2026
- US stock futures rise on tech rebound before Nvidia, inflation tests
- Oil hits one-week low as investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at JPMorgan
October 3, 2024 6:01 AM EDTJPMorgan analyst Tessa Romero raised the price target on Biohaven Pharmaceutical Holding (NYSE: BHVN) to $68.00 (from $55.00) while maintaining a Overweight rating.
The analyst comments "We are updating our model following Biohavens updates last week around their troriluzole program in spinocerebellar ataxia (SCA), where the company expects to complete resubmission of an NDA for the treatment of all SCA genotypes... More
